Bank of America Corp DE Has $9.91 Million Position in Genmab A/S (NASDAQ:GMAB)

Bank of America Corp DE lowered its position in Genmab A/S (NASDAQ:GMAB) by 55.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 474,858 shares of the company’s stock after selling 579,588 shares during the quarter. Bank of America Corp DE owned approximately 0.07% of Genmab A/S worth $9,910,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in GMAB. Brandywine Global Investment Management LLC acquired a new stake in Genmab A/S in the fourth quarter valued at $33,804,000. Marshall Wace LLP lifted its stake in Genmab A/S by 162.2% in the fourth quarter. Marshall Wace LLP now owns 1,122,296 shares of the company’s stock valued at $23,422,000 after acquiring an additional 694,243 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in Genmab A/S by 18,959.1% in the fourth quarter. Russell Investments Group Ltd. now owns 510,784 shares of the company’s stock valued at $10,660,000 after acquiring an additional 508,104 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Genmab A/S by 3,049.3% in the fourth quarter. JPMorgan Chase & Co. now owns 407,613 shares of the company’s stock valued at $8,507,000 after acquiring an additional 394,670 shares during the last quarter. Finally, Trexquant Investment LP lifted its stake in Genmab A/S by 495.1% in the fourth quarter. Trexquant Investment LP now owns 379,936 shares of the company’s stock valued at $7,929,000 after acquiring an additional 316,089 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Stock Down 1.0%

Shares of Genmab A/S stock opened at $20.81 on Friday. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $28.96. The company has a 50-day simple moving average of $19.77 and a two-hundred day simple moving average of $20.70. The stock has a market capitalization of $13.34 billion, a price-to-earnings ratio of 11.96, a price-to-earnings-growth ratio of 2.65 and a beta of 1.04.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.08. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. The business had revenue of $715.00 million during the quarter, compared to analysts’ expectations of $5.17 billion. On average, sell-side analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Sanford C. Bernstein cut shares of Genmab A/S from a “market perform” rating to an “underperform” rating in a research note on Tuesday, April 1st. William Blair upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 11th. Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price for the company in a research note on Thursday, February 13th. Truist Financial cut their target price on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. Finally, HC Wainwright restated a “buy” rating and set a $37.00 target price (down previously from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.17.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.